INTRODUCTION
Attention
In March of l995, Harold Varmus, director of NIH (National
Institutes of Health), announced in Science magazine, that he
has some doubts about trends in gene therapy. This is an alarming
comment coming from the man who delivers the final "OK" for all genetic
research. And if he is doubtful, how can we be sure that somewhere some
scientist hasn't "accidently" mutated a gene producing some
unprecedented fatal disease. (Test.)
Motivation
So what, you may ask? The gene therapy experiments being performed
today may cause you to be discriminated against in the future job
market. Your future children may be vulnerable to unimaginable genetic
defects due to premature genetic experimentation being performed as I
speak.
Thesis
The U. S. Congress should ban all genetic research until universal
guidelines are established because the current approval process is
biased and exclusive while technology is advancing too rapidly.
Ethos & Overview
Based on the research I have done, first I am going to
discuss the problems associated with the current guidelines for genetic
research, then my plan for solving this problem, and finally how my plan
would be implemented.
BODY
Transition: I'll begin with the problems that exist with the
current status quo.
I. Need Step
A. Status quo: According to the U.S. Code, the Congressional Biomedical
Ethics Board was established by Congress in l985 to evaluate the ethical
implications of genetic breakthroughs.
- Although this committee continues to exist on paper, according tothe
1991 CQ Researcher, it is inactive. (Test.)
- For a gene therapy proposal for research to pass, it must be
approved by five separate bodies including the NIH and FDA. Finally, the
director of the NIH must sign off on all experiments. (Expl.)
B. Problems:
- Federal and private research teams are not treated equally.
- According to the August 9, l99l Science magazine, the NIH
is biased because it provides funding for federal projects. (Test.)
- Research teams in the private sector can bypass the NIH in the
review process and go straight to the FDA. (Expl.)
- Many questions whether the FDA has the ability to judge whether
a gene therapy proposal is safe and effective.
- Furthermore, unsafe proposals could easily slip by because the
FDA conducts its reviews in private. (Expl.)
- The fact that the private sector can bypass parts of the review
process raises major ethical concerns.
- As the 1991 CQ Researcher points out, premature genetic
experimentation runs the risk of unleashing something dangerous and
irreversible into the human gene pool.
- The identification of possible "defective" genes could lead to
discrimination by insurance companies and employers.
- In the quest for the "perfect" child, the number of abortions
could rise significantly. (Test.)
- Gene therapy is a fairly new field - - being approved for use only
since 1990. Technology is developing so quickly that we have failed to
consider its implications. (Expl.)
Scope/Transition: Because every human being has a genetic code
that can now be manipulated, these problems affect everyone in the world.
Due to the large magnitude of these problems, we must seek a solution.
II. Satisfaction Step - - Plan/Solution
- Plan Details: My plan is to ban all genetic research until a
non-biased committee is established with strict guidelines by which both
federal and private funded research proposals must pass.
- Implementation:
- Enactment: The U.S. Congress has the power to ban all genetic
research and give review power to a committee.
- Administration: The office of Science and Technology at a
September 28, l994 hearing before Congress entitled "Gene Therapy:
Status Prospects for the Future and Government Policy Implications"
suggested that a National Bioethics Advisory Commission (NBAC)
consisting of a panel of non-governmental experts in various
disciplines be created in order to review both federal and private
research proposals.
- Enforcement: All research laboratories would have to be registered
with the NBAC and monthly check-ups would occur. Failure to follow the
designated guidelines would result in fines, suspensions, or in
extreme cases termination of research. (Expl.)
Transition: Now that you have a general understanding of my
proposed plan, let me tell you why it would be effective and the benefits
involved.
III. Visualization
- Workability: My proposed ban on gene therapy could be easily
compared with the current U.S. ban of the abortion pill RU-486.
(Analogy)
- According to U.S. News and World Reports December 27,
l993, currently clinical trials are being conducted and guidelines for
its use are being evaluated and established. (Test.)
- This ban was also imposed for the sake of human safety. (Expl.)
- Practicality: (Inoculation Theory) Probably most of you can see that
gene therapy guidelines need to be more defined, yet you may question a
temporary ban on research.
- You may be concerned that patients would be denied life-saving
techniques, yet that is not a concern. Currently gene therapy is so
experimental and expensive that it is not widely used. (Expl)
- According to the November 4, l994 Science magazine, the
NIH l995 budget for biomedical research was listed as $l.9 billion.
Therefore, the ban would be cost-effective and allow us to better
assess our need for spending. (Test. And Expl.)
- Benefits: With the implementation of my proposed plan, both federal
and private research proposals would be treated equally. The temporary
ban on genetic therapy would give everyone a better perspective on the
implications involved. (Expl.)
CONCLUSION - - Action Step
A. Underview:
As you now know, the current status quo involving gene manipulation
is ineffective. The review process is biased and exclusive to private
research. Because the private proposals are not as carefully
scrutinized, ethical concerns arise. A temporary ban on genetic research
and the establishment of a committee such as the National Bioethics
Advisory Commission would allow the current situation in gene therapy to
be assessed and stricter guidelines imposed. Much like the ban on the
abortion pill, my plan would be cost-effective and would not endanger
human lives.
B. Call for Action (involving the audience):
However, there is something that almost everyone in this room can do
to help. Carol Mosely-Braun represents you and me
in Congress. By writing to her at 708 Hart Building, Washington, D.C.
205l0, you can voice your concern about the current gene therapy review
process. But do not delay - - we must reverse the trends of gene therapy
review before the results become irreversible. (Expl.)
C. Last Thought.
As my speech comes to a close, I leave the rest up to you. We don't
have to sit here idly and watch genetic breakthroughs run out of control.
As an unknown author put rather eloquently, "A word spoken in season is
like an apple of silver, and actions are more precious than words."
WORKS CITED
Griffin, Rodman G. "Gene Therapy." C.Q. Researcher l8 Oct. l99l:
777-800.
Marshall, Elliot. "Early Budget Proposals for NIH Draw Fire".
Science 4 Nov. l994: 727
Marshall, Elliot. "Varmus Orders Up a Review of the Science of Gene
Therapy." Science l7 Mar. l995: l588.
Palca, Joseph. "Changes Ahead for Gene Therapy Review Process?"
Science 9 Aug l99l: 624-5.
Schrof, Joannie, M. "Will the Abortion Pill Remain Banned?" U.S.
News and World Report 27 Dec. l993: 78-79.
U.S. Codes. Biomedical Ethics Board. 42 USC Sec. 275.
United States. Cong. House. Committee on Science, Space and Technology.
Gene Therapy: Status, Prospects for the
Future, and Government Policy Implications. 103rd Cong.,
2nd sess. Washington: GPO, l994.
|